Matthew Weston

Stock Analyst at UBS

(0.47)

# 4,020

Out of 4,944 analysts

4

Total ratings

n/a

Success rate

-1.43%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General

Stocks Rated by Matthew Weston

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NVO Novo Nordisk	Downgrades: Neutral	n/a	$50.90	-	1	Aug 5, 2025
	NVS Novartis AG	Downgrades: Neutral	n/a	$121.20	-	1	Feb 13, 2025
	AZN AstraZeneca	Upgrades: Buy	n/a	$77.94	-	2	Feb 13, 2025

Novo Nordisk

Aug 5, 2025

Downgrades: Neutral

Price Target: n/a

Current: $50.90

Upside: -

Novartis AG

Feb 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $121.20

Upside: -

AstraZeneca

Feb 13, 2025

Upgrades: Buy

Price Target: n/a

Current: $77.94

Upside: -